KalVista Pharmaceuticals (KALV) to Release Earnings on Tuesday

KalVista Pharmaceuticals (NASDAQ:KALV) is anticipated to release its Q3 2025 results before the market opens on Tuesday, November 11th. Analysts expect KalVista Pharmaceuticals to post earnings of ($0.96) per share and revenue of $6.0330 million for the quarter. Interested persons can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Tuesday, November 11, 2025 at 8:30 AM ET.

KalVista Pharmaceuticals (NASDAQ:KALV) last released its quarterly earnings data on Thursday, September 11th. The specialty pharmaceutical company reported ($1.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.91) by ($0.21). The company had revenue of $1.43 million for the quarter, compared to analysts’ expectations of $1.97 million. On average, analysts expect KalVista Pharmaceuticals to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

KalVista Pharmaceuticals Price Performance

KALV opened at $10.78 on Friday. KalVista Pharmaceuticals has a 1-year low of $7.30 and a 1-year high of $17.28. The stock has a market cap of $544.64 million, a P/E ratio of -2.74 and a beta of -0.04. The stock’s 50 day simple moving average is $12.38 and its 200 day simple moving average is $12.83.

Analyst Upgrades and Downgrades

KALV has been the subject of several recent research reports. Needham & Company LLC restated a “buy” rating and set a $28.00 target price on shares of KalVista Pharmaceuticals in a report on Friday, September 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research note on Wednesday, October 8th. Finally, JMP Securities upped their price target on KalVista Pharmaceuticals from $27.00 to $28.00 and gave the stock a “market outperform” rating in a research note on Friday, September 12th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $26.43.

Insiders Place Their Bets

In other news, CEO Benjamin L. Palleiko sold 10,940 shares of the company’s stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $13.22, for a total transaction of $144,626.80. Following the completion of the transaction, the chief executive officer owned 386,858 shares in the company, valued at approximately $5,114,262.76. This represents a 2.75% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Paul K. Audhya sold 2,942 shares of KalVista Pharmaceuticals stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $13.22, for a total value of $38,893.24. Following the sale, the insider directly owned 119,841 shares in the company, valued at approximately $1,584,298.02. This trade represents a 2.40% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 26,856 shares of company stock valued at $374,910. 4.30% of the stock is currently owned by corporate insiders.

Institutional Trading of KalVista Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in KALV. BNP Paribas Financial Markets raised its position in KalVista Pharmaceuticals by 47.0% in the second quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock worth $46,000 after acquiring an additional 1,292 shares in the last quarter. Tower Research Capital LLC TRC boosted its holdings in shares of KalVista Pharmaceuticals by 816.8% during the second quarter. Tower Research Capital LLC TRC now owns 8,059 shares of the specialty pharmaceutical company’s stock worth $91,000 after purchasing an additional 7,180 shares during the period. Brevan Howard Capital Management LP acquired a new position in shares of KalVista Pharmaceuticals in the second quarter worth $151,000. The Manufacturers Life Insurance Company increased its holdings in KalVista Pharmaceuticals by 5.9% in the second quarter. The Manufacturers Life Insurance Company now owns 14,626 shares of the specialty pharmaceutical company’s stock worth $165,000 after buying an additional 818 shares during the last quarter. Finally, Osaic Holdings Inc. acquired a new stake in shares of KalVista Pharmaceuticals in the 2nd quarter valued at $248,000.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).